why choose us

300×250 Ad Slot

Research Article: Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

Date Published: 2023-11-15

Abstract:
Esophageal cancer (EC) is a malignancy originating from esophageal epithelial cells, recognized for its high incidence, substantial mortality, and regional predilection. Globally, its incidence is ranked seventh amongst malignant tumors, with mortality standing at sixth. On a histological level, EC can be subdivided into esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), with the latter making up around % of all EC cases. China, in particular, is an ESCC high-risk region; data from reported , new ESCC cases, with both incidence and mortality rates surpassing the Asian and global averages. Often, ESCC presents insidiously, with more than half of the patients diagnosed in the mid to late stages of the disease, resulting in a poor prognosis.

Introduction:
Esophageal cancer (EC) is a malignancy originating from esophageal epithelial cells, recognized for its high incidence, substantial mortality, and regional predilection. Globally, its incidence is ranked seventh amongst malignant tumors, with mortality standing at sixth. On a histological level, EC can be subdivided into esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC), with the latter making up around % of all EC cases. China, in particular, is an ESCC high-risk region; data from…

Read more

300×250 Ad Slot